
Florian Krackhardt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/462261/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Results from the "Me & My Heart―(eMocial) Study: a Randomized Evaluation of a New Smartphone-Based Support Tool to Increase Therapy Adherence of Patients with Acute Coronary Syndrome. Cardiovascular Drugs and Therapy, 2022, , 1.	2.6	1
2	Impact of Coronary Stent Architecture on Clinical Outcomes: Do Minor Changes in Stent Architecture Really Matter?. Cardiology and Therapy, 2021, 10, 175-187.	2.6	1
3	Propensity scoreâ€based analysis of 30â€day survival in cardiogenic shock patients supported with different microaxial left ventricular assist devices. Journal of Cardiac Surgery, 2021, 36, 4141-4152.	0.7	10
4	Polymer-free drug-coated vs. bare-metal coronary stents in patients undergoing non-cardiac surgery: a subgroup analysis of the LEADERS FREE trial. Clinical Research in Cardiology, 2021, 110, 162-171.	3.3	4
5	Clinical outcomes following polymer-free sirolimus-eluting stent implantations in unselected patients. Medicine (United States), 2020, 99, e21244.	1.0	1
6	Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet, The, 2020, 396, 1504-1510.	13.7	96
7	Endpoint selection for noninferiority percutaneous coronary intervention trials: a methodological description. Therapeutic Advances in Cardiovascular Disease, 2020, 14, 175394472091132.	2.1	2
8	Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice. Medicine (United States), 2020, 99, e19119.	1.0	6
9	Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes. PLoS ONE, 2020, 15, e0226606.	2.5	5
10	Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease. Cardiovascular Drugs and Therapy, 2020, 34, 335-344.	2.6	5
11	Systematic Scoring Balloon Lesion Preparation for Drug-Coated Balloon Angioplasty in Clinical Routine: Results of the PASSWORD Observational Study. Advances in Therapy, 2020, 37, 2210-2223.	2.9	23
12	A multicentre, randomised controlled clinical study of drug-coated balloons for the treatment of coronary in-stent restenosis. EuroIntervention, 2020, 16, e328-e334.	3.2	19
13	Patient with heart failure: importance to treat valvular diseases. European Heart Journal Supplements, 2020, 22, P38-P41.	0.1	5
14	Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts. Journal of Cardiovascular Translational Research, 2019, 12, 116-123.	2.4	125
15	Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve–Guided Strategy in Patients With or Without Type 2 Diabetes. JAMA Cardiology, 2019, 4, 857.	6.1	25
16	Sex Differences in Instantaneous Wave-Free Ratio or Fractional Flow Reserve–Guided Revascularization Strategy. JACC: Cardiovascular Interventions, 2019, 12, 2035-2046.	2.9	26
17	Design and rationale for the "Me & My Heart―(eMocial) study: A randomized evaluation of a new smartphoneâ€based support tool to increase therapy adherence of patients with acute coronary syndrome. Clinical Cardiology, 2019, 42, 1054-1062.	1.8	4
18	Clinical Events After Deferral of LADÂRevascularization Following PhysiologicalÂCoronaryÂAssessment. Journal of the American College of Cardiology, 2019, 73, 444-453.	2.8	35

FLORIAN KRACKHARDT

#	Article	IF	CITATIONS
19	Impella versus IABP in acute myocardial infarction complicated by cardiogenic shock. Open Heart, 2019, 6, e000987.	2.3	63
20	Mode-of-action of the PROPELLA concept in fulminant myocarditis. European Heart Journal, 2019, 40, 2164-2169.	2.2	49
21	Drug Coated Balloon-Only Strategy in De Novo Lesions of Large Coronary Vessels. Journal of Interventional Cardiology, 2019, 2019, 1-8.	1.2	25
22	Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471982633.	2.1	10
23	Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT). Herz, 2019, 44, 433-439.	1.1	3
24	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. EuroIntervention, 2019, 15, e1090-e1098.	3.2	16
25	Delayed coronary obstruction after lotus transcatheter aortic valve replacement treated with left main stent in stent implantation. Cardiology Journal, 2019, 26, 422-423.	1.2	1
26	Pre-Angioplasty Instantaneous Wave-Free Ratio Pullback Predicts Hemodynamic Outcome In Humans WithÂCoronary Artery Disease. JACC: Cardiovascular Interventions, 2018, 11, 757-767.	2.9	95
27	Insights into coronary collateral formation from a novel porcine semiacute infarction model. Coronary Artery Disease, 2018, 29, 127-137.	0.7	3
28	9â€month results of polymerâ€free sirolimus eluting stents in young patients compared to a septuagenarian and octogenarian allâ€comer population. Journal of Interventional Cardiology, 2018, 31, 338-344.	1.2	2
29	Drugâ€coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKETâ€ S MALL 2. Clinical Cardiology, 2018, 41, 569-575.	1.8	13
30	Efficacy of RADPAD protective drape during coronary angiography. Herz, 2018, 43, 310-314.	1.1	15
31	Propensity score matched all comers population treated with ultraâ€ŧhin strut bare metal and sirolimusâ€probucol coated drugâ€eluting stents of identical stent architecture. Catheterization and Cardiovascular Interventions, 2018, 91, 1221-1228.	1.7	6
32	FP550NINE-MONTH CLINICAL OUTCOMES IN DIALYSIS PATIENTS FOLLOWING POLYMER-FREE SIROLIMUS-ELUTING STENT IMPLANTATIONS. Nephrology Dialysis Transplantation, 2018, 33, i224-i225.	0.7	0
33	Efficacy and Safety of Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents for Chronic Total Occlusions: Insights from the Coroflex ISAR 2000 Worldwide Registry. Cardiology Research and Practice, 2018, 2018, 1-7.	1.1	2
34	The CardioMEMS system in the clinical management of end-stage heart failure patients: three case reports. BMC Cardiovascular Disorders, 2018, 18, 155.	1.7	5
35	Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2018, 11, 1437-1449.	2.9	111
36	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	13.7	555

FLORIAN KRACKHARDT

#	Article	IF	CITATIONS
37	Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet, The, 2018, 392, 849-856.	13.7	263
38	DCB meets DES. Herz, 2017, 42, 696-697.	1.1	2
39	Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. New England Journal of Medicine, 2017, 376, 1824-1834.	27.0	742
40	Polymer-free sirolimus-eluting stents in a large-scale all-comers population. Open Heart, 2017, 4, e000592.	2.3	18
41	Porcine arteriogenesis based on vasa vasorum in a novel semi-acute occlusion model using high-resolution imaging. Heart and Vessels, 2017, 32, 1400-1409.	1.2	4
42	2-Year Outcomes of HighÂBleedingÂRiskÂPatients After Polymer-Free Drug-Coated Stents. Journal of the American College of Cardiology, 2017, 69, 162-171.	2.8	109
43	Low permanent pacemaker rates following Lotus device implantation for transcatheter aortic valve replacement due to modified implantation protocol. Cardiology Journal, 2017, 24, 250-258.	1.2	8
44	Safety and efficacy of catheter-based left atrial appendage closure in patients with contraindications for long-term anticoagulation. Minerva Cardiology and Angiology, 2017, 65, 545-552.	0.7	2
45	Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2602-2605.	27.0	5
46	Postprocedural radial artery occlusion rate using a sheathless guiding catheter for left ventricular endomyocardial biopsy performed by transradial approach. BMC Cardiovascular Disorders, 2016, 16, 253.	1.7	15
47	A Rare case of single coronary artery with atherosclerotic lesions arising from the right sinus of Valsalva. North American Journal of Medical Sciences, 2016, 8, 114.	1.7	3
48	A rare case of ovarian cancer in pregnancy complicated by pulmonary embolus and myocardial infarction: management dilemmas. Journal of Surgical Case Reports, 2014, 2014, rju099-rju099.	0.4	1
49	Heart rate following shortâ€ŧerm betaâ€blocker titration predicts all ause mortality in elderly chronic heart failure patients: insights from the <scp>CIBISâ€ELD</scp> trial. European Journal of Heart Failure, 2014, 16, 907-914.	7.1	25
50	N-terminal pro-B-type natriuretic peptide and long-term mortality in non-ischaemic cardiomyopathy. Wiener Klinische Wochenschrift, 2011, 123, 738-742.	1.9	4
51	Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clinical Research in Cardiology, 2008, 97, 578-586.	3.3	50
52	Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Human Molecular Genetics, 2008, 17, 2753-2765.	2.9	142
53	Dislocation of a metal stent to the right ventricle: an unusual finding in the heart. Journal of Cardiovascular Medicine, 2008, 9, 742-743.	1.5	1
54	Modulation of Contractions to Ergonovine and Methylergonovine by Nitric Oxide and Thromboxane A2 in the Human Coronary Artery. Journal of Cardiovascular Pharmacology, 2000, 36, 631-639.	1.9	14